Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PIN + anti-PD1
- Development stage
- Unknown
- Lead developer
- Pin Therapeutics
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
PIN + anti-PD1 is a combination therapy consisting of two agents: "PIN" (identity not fully specified in the available data) and an anti-PD-1 monoclonal antibody. Anti-PD-1 antibodies are immune checkpoint inhibitors that block the programmed cell death protein 1 (PD-1) pathway, thereby enhancing T-cell mediated immune responses against cancer cells. This combination approach aims to leverage the immunomodulatory effects of both components to achieve greater antitumor efficacy than monotherapy. Anti-PD-1 therapies are approved for a wide range of cancers and are often combined with other agents—including targeted therapies, chemotherapies, or additional immunotherapies—to improve clinical outcomes[3][5][4]. The specific mechanism and role of "PIN" in this combination cannot be determined from current sources.
- Other names
- PIN + anti-PD1
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)
Beyond the preview
Go deeper on PIN + anti-PD1.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PIN + anti-PD1.